Source comparison
TB-500 with Alcohol Safety: Protocol Comparison
Wound Closure Rate (% baseline) 154% 142% 118–132% 95–110% Ethanol reduces TB-500 efficacy in dose-dependent manner. Chronic exposure negates benefit Angiogenic Marker Expression (VEGF, bFGF) +68% vs control +54% vs control +32% vs control +8–15% vs control Al
This comparison does not assign a generated winner or score.
- Wound Closure Rate (% baseline)
- 154%
- 142%
- 118–132%
- 95–110%
- Ethanol reduces TB-500 efficacy in dose-dependent manner. Chronic exposure negates benefit
- Angiogenic Marker Expression (VEGF, bFGF)
- +68% vs control
- +54% vs control
- +32% vs control
- +8–15% vs control
- Alcohol suppresses angiogenic signaling TB-500 activates. Moderate intake halves response
- Hepatic Peptide Clearance Time (hours)
- 10–12
- 12–14
- 14–18
- 18–24
- Delayed clearance increases metabolic load without improving tissue uptake
- Systemic Inflammation Markers (IL-6, TNF-alpha)
- Baseline
- +12–18%
- +35–50%
- +80–120%
- Inflammatory state directly opposes TB-500's tissue-repair signaling cascade
- Recommended Dosing Adjustment
- Standard (5 mg/kg 2x/week)
- Standard
- Increase to 7–8 mg/kg or 3x/week
- Consider alternative peptide or abstinence protocol
- Compensation possible at moderate intake; chronic high-dose use requires protocol redesign